Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Fig. 1

Flow chart for pre- and post-propensity score matching indicating the number of patients in each compared group. COVID-19, coronavirus disease 2019; DPP-4i, dipeptidyl peptidase-4 inhibitors; GLD, glucose-lowering drugs; GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose transporter 2 inhibitors; T2DM, type 2 diabetes mellitus

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us